.svg)
Atopic Dermatitis: Skin Inflammation You Can Read in Blood
Atopic dermatitis is a skin disease driven by an overactive type 2 immune response that doesn’t stay only in the skin. Blood biomarkers capture these circulating signals, allowing clinicians to gauge the intensity and pattern of inflammation, allergy tendency, and barrier stress behind the rash and itch. Typical signals include allergy antibodies (IgE) and eosinophils, which reflect atopic load; skin-homing chemokines that track disease activity (TARC/CCL17, MDC/CCL22); proteins released with tissue stress and remodeling (periostin, LDH); and cytokines that power itch and inflammation (IL-4, IL-13, IL-31, IL-22). Together, these markers make the biology of eczema measurable: they help confirm that the disease is active and systemic, differentiate endotypes (e.g., IgE-high vs IgE-low), monitor control over time, anticipate flares, and align patients with targeted treatments that block the relevant pathways (such as IL-4/IL-13 inhibitors). In short, atopic dermatitis biomarkers translate what is happening in the skin into objective numbers in the blood, complementing the skin exam with a clearer readout of the underlying immune activity.
Why an Atopic Dermatitis Blood Panel Matters
Blood tests for atopic dermatitis (AD) show how far a skin disease extends into whole‑body biology. They track allergic/type‑2 immune activity (eosinophils, often alongside total IgE) and general inflammatory tone (CRP). This helps explain itch, rash, and infections on the surface while also signaling risks in airways, sleep, and metabolic health beneath the surface.Eosinophils are normally a small slice of white cells, typically in the low single‑digit percent, with “healthier” patterns nearer the low end. CRP (a liver-made inflammation signal) is usually very low; the optimal pattern sits at the low end as well. In AD, CRP can stay normal even during flares because the disease is driven more by type‑2 cytokines than by CRP‑raising pathways; when it rises, it often hints at broader inflammation or infection.When values are low—eosinophils near the bottom of the reference interval and CRP very low—it reflects a quieter systemic immune state. AD in this setting often behaves as more skin‑limited dryness and itch with fewer infections. Children with lower eosinophils tend to have less “atopic march” toward asthma or allergic rhinitis. In pregnancy, CRP can run higher physiologically, so very low CRP is less common and results need context.Higher eosinophils point to active allergic circuitry and correlate with more intense itch, sleep disruption, and a tendency toward asthma, food sensitivity, and secondary skin infection. A clearly elevated CRP suggests superimposed infection or widespread inflammation; this is more often seen in severe adult disease.Big picture: these biomarkers connect the skin barrier to immune networks, microbiome shifts, and systemic inflammation. Tracking them alongside symptoms helps gauge disease burden, anticipate comorbid allergy and infection risk, and understand long‑term health impacts beyond the skin.
What Eczema Bloodwork Can and Can't Clarify
Blood testing for Atopic Dermatitis provides insight into how your immune system is functioning and how it may be contributing to skin inflammation. At a systems level, these tests help us understand the interplay between immunity, inflammation, and overall health—factors that can influence energy, resilience, and even cardiovascular risk. At Superpower, we focus on two key biomarkers: Eosinophils and C-reactive protein (CRP).Eosinophils are a type of white blood cell involved in allergic responses and defense against certain infections. In Atopic Dermatitis, eosinophil levels can be elevated, reflecting the immune system’s heightened activity and tendency toward allergic inflammation. CRP is a protein produced by the liver in response to inflammation anywhere in the body. While CRP is not specific to Atopic Dermatitis, higher levels can indicate ongoing systemic inflammation, which sometimes accompanies more severe or widespread skin disease.Stable, healthy levels of eosinophils suggest that the immune system is balanced and not overreacting to harmless triggers, which supports skin stability and reduces the risk of flare-ups. A normal CRP level indicates that inflammation is well-controlled, both in the skin and throughout the body, supporting overall health and resilience.Interpretation of these biomarkers can be influenced by factors such as recent infections, allergies, age, pregnancy, and certain medications. Laboratory methods and reference ranges may also vary, so results are best understood in the context of your overall health and medical history.
FAQs
It measures immune and inflammation signals that track eczema activity. Superpower tests your blood for Eosinophils (allergy-related white cells) and C‑reactive protein, CRP (an acute‑phase inflammation protein). Elevated eosinophils point to type‑2 (Th2) immune activation common in atopic dermatitis. CRP reflects whole‑body inflammation and can flag flares or intercurrent infection. These markers support, but do not replace, clinical diagnosis from skin findings.
To quantify what your immune system is doing and to track control over time. Eosinophils help gauge allergic/type‑2 activity; CRP signals systemic inflammation or infection. Together they help distinguish a flare from an infection, stage severity, and monitor response to therapy. Objective numbers complement symptoms and exam.
Yes. With Superpower, our team member can organise a blood draw in your home. Samples are processed by certified labs, and results sync to your dashboard for review.
Start with a baseline. Recheck during significant flares and after major treatment changes to confirm direction of change. For stable disease, many people repeat testing every 3–6 months to track trends. Trends, not single values, guide understanding of control.
Eosinophils rise with allergies, asthma, parasite exposure, and seasonal triggers, and vary by time of day; they fall with corticosteroids and biologics that block IL‑4/IL‑5/IL‑13. CRP rises with infections, flares, trauma, obesity, and intense exercise, and declines as systemic inflammation resolves. Recent illness and medications can shift both.
No fasting is required. Aim for a consistent time of day, since eosinophils have a diurnal pattern. Avoid heavy exercise and acute infections right before testing if you want a baseline CRP. Tell us about current steroids, biologics, or recent antibiotics, which can alter results.
References
- Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018). Atopic dermatitis. Nature Reviews. Disease Primers, 4(1), 1. https://doi.org/10.1038/s41572-018-0001-z
- Kataoka, Y. (2025). Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: Significance and limitations in the new treatment era. Frontiers in Allergy, 5, 1473902. https://doi.org/10.3389/falgy.2024.1473902
- Hill, D. A., & Spergel, J. M. (2018). The atopic march: Critical evidence and clinical relevance. Annals of Allergy, Asthma & Immunology, 120(2), 131-137. https://doi.org/10.1016/j.anai.2017.10.037
- Lambrecht, B. N., & Hammad, H. (2015). The immunology of asthma. Nature Immunology, 16(1), 45-56. https://doi.org/10.1038/ni.3049
- Hu, Y., Liu, S., Liu, P., Mu, Z., & Zhang, J. (2020). Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis. Journal of Clinical Laboratory Analysis, 34(6), e23214. https://doi.org/10.1002/jcla.23214
.avif)
.svg)
.svg)
